These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 1538475)
1. Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. Cho YH; Straight RC; Smith JA J Urol; 1992 Mar; 147(3):743-6. PubMed ID: 1538475 [TBL] [Abstract][Full Text] [Related]
2. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer. Shapiro A; Ratliff TL; Oakley DM; Catalona WJ J Urol; 1984 Jan; 131(1):139-42. PubMed ID: 6418894 [TBL] [Abstract][Full Text] [Related]
4. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment. Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699 [TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041 [TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin immunotherapy. Techniques and results. Brosman SA Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239 [TBL] [Abstract][Full Text] [Related]
7. Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. Svatek RS; Zhao XR; Morales EE; Jha MK; Tseng TY; Hugen CM; Hurez V; Hernandez J; Curiel TJ Clin Cancer Res; 2015 Jan; 21(2):303-11. PubMed ID: 25424854 [TBL] [Abstract][Full Text] [Related]
8. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868 [TBL] [Abstract][Full Text] [Related]
10. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model. Steinberg GD; Brendler CB; Squire RA; Isaacs JT J Urol; 1991 Mar; 145(3):647-53. PubMed ID: 1997724 [TBL] [Abstract][Full Text] [Related]
11. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG? Badalato GM; Hruby G; Razmjoo M; McKiernan JM Can J Urol; 2011 Oct; 18(5):5890-5. PubMed ID: 22018151 [TBL] [Abstract][Full Text] [Related]
12. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808 [TBL] [Abstract][Full Text] [Related]
13. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Smaldone MC; Gayed BA; Tomaszewski JJ; Gingrich JR Minerva Urol Nefrol; 2009 Jun; 61(2):71-89. PubMed ID: 19451890 [TBL] [Abstract][Full Text] [Related]
14. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147 [TBL] [Abstract][Full Text] [Related]
15. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427 [TBL] [Abstract][Full Text] [Related]
16. Treatment of superficial bladder cancer with intravesical chemotherapy. Badalament RA; Farah RN Semin Surg Oncol; 1997; 13(5):335-41. PubMed ID: 9259089 [TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. Pisters LL; Tykochinsky G; Wajsman Z J Urol; 1991 Dec; 146(6):1514-7. PubMed ID: 1942330 [TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955 [TBL] [Abstract][Full Text] [Related]
20. Bladder carcinoma--the good, the bad and the ugly. Manyak MJ J Urol; 1996 Jan; 155(1):103-4. PubMed ID: 7490802 [No Abstract] [Full Text] [Related] [Next] [New Search]